arrow
S

Sosana Delimpasi

evangelismos general hospital
H指数:25
被引数:4,414

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pharmacokinetics and safety of belantamab mafodotin monotherapy in patients with relapsed/refractory multiple myeloma who have normal and varying degrees of impaired renal function

belantamab mafodotin单药治疗在具有正常肾功能和不同程度肾功能损害的复发/难治性多发性骨髓瘤患者中的药代动力学与安全性

2026-05-250
OAAI
BRIDGE (OP-107): A Phase 2 Pharmacokinetic Study of Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Impaired Renal Function

BRIDGE (OP-107):美法仑肽联合地塞米松治疗肾功能受损的复发/难治性多发性骨髓瘤患者的2期药代动力学研究

2026-04-300
OAAI
Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide-refractory multiple myeloma: Subgroup analysis of the BOSTON trial

塞利尼索剂量减量对lenalidomide难治性多发性骨髓瘤患者应用塞利尼索、硼替佐米和地塞米松治疗结局的影响:BOSTON试验的亚组分析

2026-04-140
OA
Real-World Outcomes in NPM1-Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse

NPM1突变急性髓系白血病中的真实世界结局:可测量微小残留病对疾病复发的影响

2026-04-100
PRE
Clinical outcomes in newly diagnosed patients with Waldenström's macroglobulinaemia treated in a tertiary academic centre

新诊断的华氏巨球蛋白血症患者在三级学术中心治疗后的临床结局

2026-01-220
PRE
Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study

皮下注射达雷木单抗联合卡非佐米和地塞米松(D-Kd)与卡非佐米和地塞米松(Kd)在既往接受过达雷木单抗治疗的患者中的比较:LYNX研究

2025-10-010
PRE
Modification of Belantamab Mafodotin Dosing to Balance Efficacy and Tolerability in the DREAMM-7 and DREAMM-8 Trials

在DREAMM-7和DREAMM-8试验中调整Belantamab Mafodotin给药剂量以平衡疗效和耐受性

2025-08-070
OAAI
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide

贝兰他单抗马福替尼联合泊马利度胺和地塞米松与泊马利度胺联合硼替佐米和地塞米松治疗复发/难治性多发性骨髓瘤:在接受过包含来那度胺的1线先前治疗的患者亚组分析

BLOOD
IF23.1
2024-11-053
PRE
Second primary malignancies and disease transformation in symptomatic patients with Waldenstrom's macroglobulinemia: Outcomes of a population-based analysis

症状性华氏巨球蛋白血症患者中第二原发恶性肿瘤及疾病转化:一项基于人群分析的结果

2024-09-010
PRE
Central nervous system multiple myeloma: A real-world multi-institutional study of the Greek Myeloma Study Group
2024-07-020
PRE
Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma
2024-06-100
OAAI
Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA
2024-01-313
OAAI
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study
2023-10-0133
PRE
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3trial
2023-10-018
PRE
Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study
2023-06-218
OA
Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab-based quadruplets: A multicenter study by the Greek myeloma study group
2023-03-1610
PRE
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis
2022-06-0413
OA
Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone +/- subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial
2022-02-067
PRE
Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study
2021-12-299
OA